Inka obtained her PhD in Immunology from the Tufts Medical School in Boston studying the molecular aspects of DNA breaks and repair. During her study, she joined Prof. Fred Alt’s group at the Harvard Medical School as a visiting scientist to validate the function of an enhancer element during V(D)J recombination and its potential contribution to chromosomal translocations in B and T lymphocytes. During her two postdoctoral fellowships at the Max-Planck Institute for Immunobiology and Epigenetics and the Netherlands Cancer Institute, she studied how chromatin modifiers and associated small molecule inhibitors regulate stem cell development and contribute to cell fate transitions and tumorigenesis. Her work focused on B cell lymphomas, prostate cancer and gliomas. After her move to industry, Inka was a senior scientist at Leica Biosystems where she developed novel molecular diagnostic tests for oncology. This work included the development of CDx projects and PoC studies for biomarkers particularly for circulating tumor cells to screen various tumor types including lung, breast and bladder cancer.
Inka joined SMS-oncology in 2017 as a Consultant and was promoted in 2019 to Director Oncology Drug Development. She has been involved in the development of numerous clinical development plans, study design advice and writing of protocol (synopsis) for several trials in (immuno-)oncology and hemato-oncological indications.